

Staphylococcus, Candida, Aspergillus, Cryptococcus, Plasmodium, Trypanosoma, Leishmania, a gastrointestinal nematode, a helminth, Cryptosporidium, Toxoplasma, Pneumocystis, Schistosoma, or Strongyloides stercoralis.

- (000788) 17. The method of claim 16 wherein the compound is 16 β -bromo-
5 3 β -hydroxy-5 α -androstan-17-one, 16 α -bromo-3 β -hydroxy-5 α -androstan-17-one,
16 α -bromo-3 β -hydroxy-5 α -androstan-17-one hemihydrate, 16 β -chloro-3 β -hydroxy-
5 α -androstan-17-one, 16 α -chloro-3 β -hydroxy-5 α -androstan-17-one, 3 β ,16 α -
dihydroxy-5 α -androstan-17-one, 3 β ,16 β -dihydroxy-5 α -androstan-17-one,
3 β ,16 α ,17 β -trihydroxy-5 α -androstane, 3 β ,16 β ,17 β -trihydroxy-5 α -androstane or
10 3 α ,16 α ,17 β -trihydroxy-5 α -androstane.

(000789) 18. The method of claim 17 wherein the pathogen infection is an
intracellular bacterium infection.

(000790) 19. The method of claim 18 wherein the intracellular bacterium
infection is a *Mycobacterium* infection and the subject is a human.

- Rule 1.126
15 (000791) 20. The method of claim 17 wherein the pathogen infection is an
hepatitis B virus, poxvirus, Dengue virus, papillomavirus, a togavirus, or a flavivirus
infection.

- 20 (000792) 21. The method of claim 17 wherein the pathogen infection is a
fungus infection or a yeast infection.

- 20 (000793) 22. The method of claim 20 wherein the fungus infection or yeast
infection is a *Candida*, *Aspergillus*, or a *Cryptococcus* infection and the subject is a
human.

- 25 (000794) 23. The method of claim 17, wherein the pathogen infection is a
parasite infection.

- 25 (000795) 24. The method of claim 22, wherein the parasite infection is a
Plasmodium infection, a *Trypanosoma* infection, a *Leishmania* infection, a
Schistosoma infection or a *Cryptosporidium* infection.

- 30 (000796) 25. The method of claim 23 wherein the compound is 16 α -bromo-
3 β -hydroxy-5 α -androstan-17-one or 16 α -bromo-3 β -hydroxy-5 α -androstan-17-one
hemihydrate and the infection is a *Plasmodium* infection and the subject is a human.

(000797) 25. A composition comprising 16 α -bromo-3 β -hydroxy-5 α -androstan-17-one, 16 α -bromo-2-oxa-3 β -hydroxy-5 α -androstan-17-one, 16 α -bromo-3 β -hydroxy-11-oxa-5 α -androstan-17-one or 16 α -bromo-3 β -hydroxy-5 α -androstan-17-one hemihydrate and one or more nonaqueous liquid excipients, wherein the

5 composition comprises less than about 3% v/v water.

(000798) 27. The composition of claim 25 wherein the composition comprises less than about 0.3% v/v water.

10 (000799) 28. The composition of claim 25 wherein the one or more nonaqueous liquid excipients are two or more of an alcohol, a polyethylene glycol, propylene glycol and benzyl benzoate.

(000800) 29. The composition of claim 25 wherein the composition is a parenteral formulation.